

# ISO/TS 17137:2021-09 (E)

## Cardiovascular implants and extracorporeal systems - Cardiovascular absorbable implants

---

<b>Contents</b>		<b>Page</b>
Foreword .....		v
Introduction .....		vi
<b>1</b>	<b>Scope .....</b>	<b>1</b>
<b>2</b>	<b>Normative references .....</b>	<b>1</b>
<b>3</b>	<b>Terms and definitions .....</b>	<b>2</b>
<b>4</b>	<b>Device design, fabrication, packaging, and use considerations .....</b>	<b>2</b>
4.1	Classification .....	2
4.2	Intended clinical performance .....	3
4.3	Intended clinical use .....	3
4.4	Materials .....	3
4.5	Packaging, labelling and sterilization .....	4
4.5.1	Packaging .....	4
4.5.2	Labelling .....	4
4.5.3	Sterilization .....	5
4.6	Product shelf-life considerations .....	6
4.6.1	General information .....	6
4.6.2	Real-time aging .....	6
4.6.3	Accelerated aging .....	7
4.7	Risk management .....	7
4.7.1	General .....	7
4.7.2	Failure modes .....	7
4.7.3	Risk mitigation .....	8
4.7.4	Specific aspects for absorbable implants .....	8
<b>5</b>	<b>Design evaluation .....</b>	<b>9</b>
5.1	Evaluation overview and general considerations .....	9
5.1.1	Overview .....	9
5.1.2	General considerations .....	11
5.2	In vitro procedural evaluation .....	12
5.2.1	Summary of in vitro evaluation steps .....	12
5.2.2	Conditioning of test samples .....	13
5.2.3	Assessment of delivery and placement .....	13
5.2.4	Assessment of initial function post-deployment .....	14
5.3	In vitro degradation evaluation .....	14
5.3.1	General .....	14
5.3.2	Sample conditioning .....	15
5.3.3	Mechanical evaluation .....	15
5.3.4	Cyclic fatigue durability evaluation .....	16
5.3.5	Physical and chemical degradation evaluation .....	17
5.3.6	Imaging compatibility evaluation .....	20
5.4	Biological evaluation .....	20
5.4.1	General considerations .....	20
5.4.2	Particulate observation, measurement and assessment -- In vivo .....	21
5.4.3	Sterilization considerations .....	21
5.4.4	Drug-device combination product considerations .....	22
5.5	In vitro-in vivo correlation (IVIVC) .....	22

<b>5.6</b>	<b>In vivo preclinical evaluation .....</b>	<b>22</b>
<b>5.6.1</b>	<b>Purpose .....</b>	<b>22</b>
<b>5.6.2</b>	<b>Specific objectives .....</b>	<b>23</b>
<b>5.6.3</b>	<b>Protocol .....</b>	<b>24</b>
<b>5.6.4</b>	<b>Data collection .....</b>	<b>26</b>
<b>5.6.5</b>	<b>Test report and additional information .....</b>	<b>26</b>
<b>5.7</b>	<b>Clinical evaluation .....</b>	<b>27</b>
<b>5.7.1</b>	<b>Purpose .....</b>	<b>27</b>
<b>5.7.2</b>	<b>Specific objectives .....</b>	<b>27</b>
<b>5.7.3</b>	<b>Clinical investigation plan (CIP) .....</b>	<b>28</b>
<b>5.7.4</b>	<b>Data collection .....</b>	<b>29</b>
<b>5.7.5</b>	<b>Final report .....</b>	<b>29</b>
<b>5.8</b>	<b>Post-market surveillance .....</b>	<b>29</b>
<b>5.9</b>	<b>Select clinical trials of absorbable cardiovascular implants .....</b>	<b>29</b>
	<b>Annex A (informative) Explanation on nomenclature of absorb, degrade and related terms .....</b>	<b>31</b>
	<b>Bibliography .....</b>	<b>32</b>